<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00640406</url>
  </required_header>
  <id_info>
    <org_study_id>C0701</org_study_id>
    <nct_id>NCT00640406</nct_id>
  </id_info>
  <brief_title>Comparison of Best Medical Treatment Versus Best Medical Treatment Plus Renal Artery Stenting</brief_title>
  <acronym>RADAR</acronym>
  <official_title>A Randomized, Multi-centre, Prospective Study Comparing Best Medical Treatment Versus Best Medical Treatment Plus Renal Artery Stenting in Patients With Hemodynamically Relevant Atherosclerotic Renal Artery Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical investigation is a prospective, international, multi-centre, randomized (1:1)&#xD;
      trial with follow ups at 2, 6, 12 months and 3 years.&#xD;
&#xD;
      The purpose of the study is to evaluate the clinical impact of percutaneous transluminal&#xD;
      renal artery stenting (PTRAS) on the impaired renal function measured by the estimated&#xD;
      Glomerular Filtration Rate (eGFR) in patients with hemodynamically significant&#xD;
      atherosclerotic renal artery stenosis (ARAS).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference between treatments in change of estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Renal Artery Stenosis</condition>
  <arm_group>
    <arm_group_label>STN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Device: Dynamic Renal Stent plus Best Medical Treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Best Medical Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dynamic Renal Stent plus Best Medical Treatment</intervention_name>
    <description>percutaneous transluminal angioplasty of the kidney artery at index procedure followed by best medical treatment for hypertension secondary to renal artery stenosis according to local standards</description>
    <arm_group_label>STN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Best Medical Treatment</intervention_name>
    <description>best medical treatment for hypertension secondary to renal artery stenosis according to local standards</description>
    <arm_group_label>BMT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Informed consent signed by patient (and/or legal guardian),&#xD;
&#xD;
          -  Hemodynamically relevant de novo unilateral or bilateral atherosclerotic renal artery&#xD;
             diameter stenosis RAS (≥ 70%)&#xD;
&#xD;
          -  Estimated GFR &gt; 10 ml/min calculated using the abbreviated Modification of Diet in&#xD;
             Renal Disease (MDRD) Study equation,&#xD;
&#xD;
          -  Patients presenting mild, moderate or severe hypertension (defined according to the&#xD;
             WHO guidelines) and/or renal dysfunction,&#xD;
&#xD;
          -  Target lesion must be completely coverable by one study stent,&#xD;
&#xD;
          -  Total target lesion length estimated to be less than 19 mm,&#xD;
&#xD;
          -  Target lesion accessible to direct stenting or, after pre-dilation, is likely to&#xD;
             sufficiently benefit from stenting (at the discretion of the investigator),&#xD;
&#xD;
          -  Renal reference vessel diameter (RVD) of ≥ 4.0 mm and &lt; 7.0 mm based on visual&#xD;
             estimation,&#xD;
&#xD;
          -  Willingness to comply with all the specified follow-up evaluations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Estimated GFR ≤ 10 ml/min,&#xD;
&#xD;
          -  Renal atrophy or kidney length &lt; 7cm (referring to kidney with target lesion),&#xD;
&#xD;
          -  Patient not eligible for PTRAS,&#xD;
&#xD;
          -  Patient not eligible for stenting,&#xD;
&#xD;
          -  Target lesion occlusion,&#xD;
&#xD;
          -  Target lesion and/or target vessel proximal to the target lesion is severely&#xD;
             calcified,&#xD;
&#xD;
          -  Treatment of branch lesion required,&#xD;
&#xD;
          -  Fresh thrombus or embolic lesion&#xD;
&#xD;
          -  Need for embolic protection in previous or planned PTRAS,&#xD;
&#xD;
          -  Clotting disorders,&#xD;
&#xD;
          -  INR &gt; 2.5 before the intervention,&#xD;
&#xD;
          -  Patient presents fibromuscular dysplasia,&#xD;
&#xD;
          -  Prior revascularization of target lesion,&#xD;
&#xD;
          -  History of target vessel revascularization within the last six months,&#xD;
&#xD;
          -  Angiographic restenosis of any segment of the target vessel that has undergone prior&#xD;
             percutaneous intervention,&#xD;
&#xD;
          -  Any thrombolytic therapy procedure within 72 hours prior to planned study procedure&#xD;
&#xD;
          -  Active peptic ulcer or gastro intestinal bleeding,&#xD;
&#xD;
          -  Active inflammation of the kidney interfering with diagnosis and treatment of RAS&#xD;
             (e.g. glomerulonephritis, aortitis, vasculitis),&#xD;
&#xD;
          -  Radiation damage of the kidney,&#xD;
&#xD;
          -  Renal disease associated with aortic aneurysm i.e. diameter of the aorta &gt; 40 mm,&#xD;
&#xD;
          -  Chronic renal replacement therapy,&#xD;
&#xD;
          -  Life expectancy &lt; 1 year,&#xD;
&#xD;
          -  Co-morbid conditions limiting participation and follow-up&#xD;
&#xD;
          -  Patient currently participating in another trial possibly influencing the safety of&#xD;
             the patient and/or the outcomes of the study,&#xD;
&#xD;
          -  Pregnancy/Planned pregnancy/Childbearing potential without sufficient measures to&#xD;
             prevent pregnancy as judged by the investigator,&#xD;
&#xD;
          -  Known allergy to contrast medium that cannot be adequately controlled with&#xD;
             pre-medication,&#xD;
&#xD;
          -  Known intolerance against acetylic-salicylic acid (ASA), heparin, clopidogrel and&#xD;
             ticlopidin, cobalt-chromium,&#xD;
&#xD;
          -  Metformin intake not stopped at least 48 hours before the intervention&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Zeller, PD Dr. med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dep. of Angiology, Herzzentrum Bad Krozingen, Südring 15, 79189 Bad Krozingen, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herzzentrum Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <state>Baden-Württemberg</state>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>March 17, 2008</study_first_submitted>
  <study_first_submitted_qc>March 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2008</study_first_posted>
  <last_update_submitted>July 20, 2015</last_update_submitted>
  <last_update_submitted_qc>July 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Artery Obstruction</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

